BLASTS 10 PERCENT OR MORE OF BONE MARROW NUCLEATED CELLS
Clinical trials for BLASTS 10 PERCENT OR MORE OF BONE MARROW NUCLEATED CELLS explained in plain language.
Never miss a new study
Get alerted when new BLASTS 10 PERCENT OR MORE OF BONE MARROW NUCLEATED CELLS trials appear
Sign up with your email to follow new studies for BLASTS 10 PERCENT OR MORE OF BONE MARROW NUCLEATED CELLS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New chemo cocktail targets tough leukemias
Disease control Recruiting nowThis phase 2 trial is testing a combination of four chemotherapy drugs—cladribine, idarubicin, cytarabine, and venetoclax—in people with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blast-phase chronic myeloid leukemia. The goal is to see if this mix can kill ca…
Matched conditions: BLASTS 10 PERCENT OR MORE OF BONE MARROW NUCLEATED CELLS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Heart shield: new trial aims to prevent chemo side effects in blood cancer patients
Symptom relief Recruiting nowThis study tests whether a drug called dexrazoxane can protect the heart from damage caused by chemotherapy in people with certain blood cancers, such as acute myeloid leukemia and high-risk myelodysplastic syndrome. About 100 participants will receive dexrazoxane alongside stand…
Matched conditions: BLASTS 10 PERCENT OR MORE OF BONE MARROW NUCLEATED CELLS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC